Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SOPHIRIS BIO INC. | exhibit1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | November 5, 2013 |
Sophiris Bio Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| British Columbia | 001-36054 | 98-1008712 |
|
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 1258 Prospect Street, La Jolla, California | 92037 | |
|
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 858-777-1760 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
(d) On November 5, 2013, Sophiris Bio Inc. (the "Company") announced that it had applied to the Toronto Stock Exchange (the "TSX") to voluntarily delist from trading its shares of common stock. The TSX has indicated that effective at market close on November 13, 2013, the Company’s common stock will no longer be traded through the facilities of the TSX. The Company’s shares are currently traded, and will continue to be traded, on the NASDAQ Global Market under the symbol "SPHS".
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Sophiris Bio Inc. | ||||
| November 5, 2013 | By: |
/s/ Peter T. Slover
|
||
|
|
||||
| Name: Peter T. Slover | ||||
| Title: Chief Financial Officer | ||||
Exhibit Index
| Exhibit No. | Description | |
|
|
|
|
|
99.1
|
Press Release dated November 5, 2013. |